← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
AntibodystaleGenentech, Inc.Phase 3

Cevostamab (Cevostamab)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+3
임상시험 10상태 RECRUITING
CGTBiologicstaleShenzhen Celconta Life Science …Phase 1

Claudin18.2-targeted CAR-T Cells (Claudin18.2-targeted CAR-T Cells)

Colorectal Neoplasia · Colorectal Neoplasia

#ColorectalNeoplasia#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 10상태 RECRUITING
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 10상태 ACTIVE
AntibodystaleSanofiPreclinical

Dupilumab - Standard Dose (Dupilumab - Standard Dose)

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP); Smell Loss · Atopic Dermatitis

#AtopicDermatitis#Antibody#Preclinical#항체#면역항체+4
임상시험 10상태 RECRUITING
ADCBiologicstaleCuris, Inc.Phase 1

Emavusertib (Emavusertib)

Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 10상태 RECRUITING
CGTBiologicstaleChongqing University Cancer Hos…Phase 2

Oncolytic Virus H101 (Oncolytic Virus H101)

Rectal Neoplasms; Rectal Adenocarcinoma · Rectal Neoplasms

#RectalNeoplasms#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 10상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab Injection [Keytruda])

Gestational Trophoblastic Neoplasia · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+3
임상시험 10상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 3

R-mini-CHOP (R-mini-CHOP)

Large B-cell Lymphoma · DLBCL

#DLBCL#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 94.1%임상시험 10상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 2

Taselisib (Taselisib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 50%임상시험 10상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 1.4%임상시험 10상태 DISCONTINUED
CGTBiologicstaleNovartisPhase 1

huCART19 (huCART19)

Acute Lymphocytic Leukemia; Diffuse Large Cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 10상태 ACTIVE
CGTBiologicstaleImmunityBio, Inc.Phase 1

super NK cell (super NK cell)

AML, Adult; Minimal Residual Disease · AML, Adult

#AMLAdult#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 0%임상시험 10상태 ACTIVE
CGTBiologicMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma · B-Cell Neoplasm

#B-CellNeoplasm#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 10상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Amcenestrant (Amcenestrant)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 42.3%임상시험 9상태 RECRUITING
ADCBiologicstaleThe Thai Lymphoma Study GroupPhase 2

B-MAD chemotherapy (B-MAD chemotherapy)

Extranodal NK/T-cell Lymphoma · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 9상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin-Blmf)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 6%임상시험 9상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 2

CHEP (CHEP)

Lymphoma; Adult T-Cell Leukemia/Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 2%임상시험 9상태 RECRUITING
ADCBiologicstaleCSPC ZhongQi Pharmaceutical Tec…Phase 3

DP303c (DP303c)

HER2-positive Breast Cancer · Localized Advanced or Metastatic Gastric

#LocalizedAdvancedorMetastaticGas#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 9상태 RECRUITING
AntibodystalePfizerPhase 2

Elranatamab + lenalidomide + dexamethasone (Elranatamab + lenalidomide + dexamethasone)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 9상태 DISCONTINUED
AntibodystaleGlaxoSmithKlinePhase 2

Feladilimab (Feladilimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 44%임상시험 9상태 RECRUITING

47 / 209 페이지

← 이전다음 →